127 related articles for article (PubMed ID: 28314296)
1. Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
D'Onofrio M; Cingarlini S; Ortolani S; Crosara S; DE Robertis R; Vallerio P; Grego E; Ciaravino V; Ruzzenente A; Landoni L; Scarpa A; Bassi C; Tortora G
Anticancer Res; 2017 Mar; 37(3):1305-1311. PubMed ID: 28314296
[TBL] [Abstract][Full Text] [Related]
2. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents.
Ng CS; Wei W; Duran C; Ghosh P; Anderson EF; Chandler AG; Yao JC
Abdom Radiol (NY); 2018 Jul; 43(7):1661-1669. PubMed ID: 29075824
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.
Takumi K; Fukukura Y; Higashi M; Ideue J; Umanodan T; Hakamada H; Kanetsuki I; Yoshiura T
Eur J Radiol; 2015 Aug; 84(8):1436-1443. PubMed ID: 26022520
[TBL] [Abstract][Full Text] [Related]
4. Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor.
Choi SH; Kim HJ; Kim SY; Byun JH; Kim KW; Song KB; Kim SC; Kim MH
Pancreas; 2017 Sep; 46(8):1056-1063. PubMed ID: 28787330
[TBL] [Abstract][Full Text] [Related]
5. Application of low dose pancreas perfusion CT combined with enhancement scanning in diagnosis of pancreatic neuroendocrine tumors.
Wan Y; Hao H; Meng S; Li Z; Yu F; Meng Chi ; Chao Q; Gao J
Pancreatology; 2021 Jan; 21(1):240-245. PubMed ID: 33191144
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance.
Lee NJ; Hruban RH; Fishman EK
Abdom Radiol (NY); 2018 Nov; 43(11):3025-3034. PubMed ID: 29594467
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography and magnetic resonance imaging features of lipid-rich neuroendocrine tumors of the pancreas.
Fukukura Y; Shindo T; Higashi M; Takumi K; Umanodan T; Yoneyama T; Yoshiura T
World J Gastroenterol; 2015 Sep; 21(34):10008-17. PubMed ID: 26379406
[TBL] [Abstract][Full Text] [Related]
8. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
9. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
10. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
11. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors.
Yao JC; Phan AT; Hess K; Fogelman D; Jacobs C; Dagohoy C; Leary C; Xie K; Ng CS
Pancreas; 2015 Mar; 44(2):190-7. PubMed ID: 25426617
[TBL] [Abstract][Full Text] [Related]
12. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
13. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Kulke MH
J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
[No Abstract] [Full Text] [Related]
14. CT Perfusion Characteristics Identify Metastatic Sites in Liver.
Wang Y; Hobbs BP; Ng CS
Biomed Res Int; 2015; 2015():120749. PubMed ID: 26509144
[TBL] [Abstract][Full Text] [Related]
15. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.
Morsbach F; Pfammatter T; Reiner CS; Fischer MA; Sah BR; Winklhofer S; Klotz E; Frauenfelder T; Knuth A; Seifert B; Schaefer N; Alkadhi H
Invest Radiol; 2013 Nov; 48(11):787-94. PubMed ID: 23748229
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.
Hudson JM; Singh S; Milot L; Patel C; Bailey C; Rodriguez-Freixinos V; Chan D; Hallet J; Law C; Myrehaug S
Anticancer Res; 2022 Jul; 42(7):3523-3527. PubMed ID: 35790284
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography.
Dörffel Y; Wermke W
Ultraschall Med; 2008 Oct; 29(5):506-14. PubMed ID: 19241507
[TBL] [Abstract][Full Text] [Related]
18. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
19. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis.
Wang Y; Huang K; Chen J; Luo Y; Zhang Y; Jia Y; Xu L; Chen M; Huang B; Ni D; Li ZP; Feng ST
Contrast Media Mol Imaging; 2018; 2018():6037273. PubMed ID: 30510495
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
